Fondazione Italiana Linfomi - Ets

This Phase 2 trial is testing a drug called glofitamab in 41 people with mantle cell lymphoma whose cancer did not respond or came back after CAR T-cell therapy. The goal is to see if glofitamab can shrink or control the cancer. Researchers will measure how many patients achieve …

This phase 3 trial is testing whether adding the targeted drug obinutuzumab to standard radiotherapy improves outcomes for people with early-stage follicular lymphoma. About 190 participants will be randomly assigned to receive either radiotherapy alone or radiotherapy followed b…

This study tests whether adding daratumumab to standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare and aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the com…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (BEGEV) helps people with Hodgkin's lymphoma that has returned or not responded to first treatment. About 122 adults aged 18-60 will receive the combination before a stem cell transplant.…

This phase 2 trial is testing whether combining two drugs, mosunetuzumab and zanubrutinib, can help people with follicular lymphoma whose cancer has returned or stopped responding to previous treatment. The study will enroll 56 participants and measure how many achieve a complete…

This phase 2 trial is testing whether the drug loncastuximab tesirine, given after a short course of chemotherapy, can help people with mantle cell lymphoma whose cancer has returned or not responded to previous treatments, including BTK inhibitors. About 49 participants will rec…

This phase 2 trial is testing a combination of two drugs, rituximab and golcadomide, as a first treatment for older frail patients with diffuse large B-cell lymphoma who cannot have standard chemotherapy. The study aims to see if this chemo-free approach can control the cancer an…

This study tests a drug called tislelizumab in people with newly diagnosed Hodgkin lymphoma who are not able to receive standard chemotherapy. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in this phase 2 trial.

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…

This study looks back at 43 cases of primary cardiac lymphoma, a very rare cancer that starts in the heart. Researchers want to learn how the disease behaves and how it has been treated in Italy over the past 20 years. The goal is to find patterns that can help doctors make bette…

This study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are treated with newer monoclonal antibodies. Researchers will track how well the cancer responds, how long patients live without the disease getting worse, and any side effects. The goal is to see how …

This study analyzes stored blood and tissue samples from 654 people with follicular lymphoma to learn how certain genetic changes affect the disease. Researchers are focusing on a gene called EZH2 and other biomarkers. The goal is to better understand the disease, not to test a n…

This study observes 200 people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma to understand how MYC gene changes relate to the disease and the immune environment. Researchers will review medical records and collect samples to find patterns that may guide future …

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. The goal is to learn whether simpl…

This study will review the medical records of 200 people diagnosed with plasmablastic lymphoma, a rare blood cancer, between 2000 and 2022. Researchers want to learn more about the disease's features, treatments used, and what affects survival. No new treatments are given; the go…

This study looks back at medical records of 400 adults with cutaneous T-cell lymphoma (CTCL) to see which systemic therapies doctors actually use and in what order. It aims to describe real-world treatment patterns, not test a new drug. The results may help guide future treatment…